| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514080000 |
Polycylo ring system having a ring nitrogen in the system
| 485 |
| 514089000 |
Hetero ring is six-membered and includes only one ring nitrogen
| 193 |
| 514091000 |
Hetero ring is five-membered
| 167 |
| 514085000 |
Hetero ring is six-membered consisting of two nitrogens and four carbons
| 94 |
| 514084000 |
Hetero ring is six-membered consisting of three nitrogens and three carbons | 5 |
| 20090005346 | Azacytosine Derivatives Useful as Antiviral Agents - The present invention provides 5-azacytosine derivatives with antiviral activity, specifically having viral replication inhibiting properties, more particularly in DNA viruses such as pox-, papilloma- and herpes viruses in humans. The invention also provides pharmaceutical compositions comprising such 5-azacytosine derivatives as active ingredients in combination with pharmaceutically acceptable carriers, which are useful for the treatment of subjects suffering from viral infections. | 01-01-2009 |
| 20090082310 | PRODRUGS OF THYROID HORMONE ANALOGS - Provided herein are compounds of the formula (I): | 03-26-2009 |
| 20140066406 | Phosphorus Derivatives as Kinase Inhibitors - The invention features compounds of the general formula: | 03-06-2014 |
| 20150065466 | NOVEL DXR INHIBITORS FOR ANTIMICROBIAL THERAPY - The present invention generally concerns particular methods and compositions for antimicrobial therapy. In particular embodiments, the compositions target DXR. In some cases, the antimicrobial agent comprises an electron-deficient hydrophobic group that has interacts with Trp211 of DXR. In specific embodiments, the compound contains electron-deficient heterocyclic rings that specifically interact with the electron-rich indole ring of Trp211. In certain aspects, the compositions comprise a phosphate group, a pyridine group, and a hydroxymate group. | 03-05-2015 |
| 20150111857 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT - Compounds and compositions useful for treating disorders related to KIT and PDFGR are described herein. | 04-23-2015 |
| 514083000 |
Hetero ring is three-membered consisting of one nitrogen and two carbons | 3 |
| 20090062236 | Programmable genotoxic agents and uses therefor - The compositions and methods disclosed herein provide heterobifunctional programmable genotoxic compounds that can be designed to kill selected cells present in a heterogenous cell population. The present compounds comprise a first agent that inflicts damage on cellular DNA, and a second agent that attracts a macromolecular cell component such as a protein, which in turn shields genomic lesions from repair. Unrepaired lesions therefore persist in the cellular genome and contribute to the death of selected cells. In contrast, lesions formed in nonselected cells, which lack the cell component, are unshielded and thus are repaired. As a result, compounds described herein are less toxic to nonselected cells. Compounds of this invention can be designed to cause the selective killing of transformed cells, viral-infected cells and the like. | 03-05-2009 |
| 20130225528 | Phosphorus Derivatives as Kinase Inhibitors - The invention features compounds of the general formula: | 08-29-2013 |
| 20140315863 | TREATING BLADDER CANCER PATIENTS AND IDENTIFYING BLADDER CANCER PATIENTS RESPONSIVE TO TREATMENT - This documents provided methods and materials involved in treating bladder cancer. This document also provides methods and materials involved in identifying bladder cancer patients likely or unlikely to respond to treatment (e.g., BCG therapy). | 10-23-2014 |
| Entries |
| Document | Title | Date |
|---|
| 20110245204 | CYCLOALKANE-CONTAINING SPHINGOSINE 1-PHOSPHATE AGONISTS - The present invention provides sphingosine-1-phosphate analogs that are potent, and selective agonists at one or more S1P receptors, specifically the S1P | 10-06-2011 |
| 20120065168 | Pharmaceutical Hypocholesterolemic Compositions - The present invention relates to novel azetidinone-containing compounds having a novel side-chain which is attached to the aryl ring at C4 via a C—C bond and comprises a 3,3-disubstituted oxetane ring and a polar group A, and which are useful in the treatment and prevention of atherosclerosis and for the reduction of cholesterol levels. | 03-15-2012 |
| 20120071446 | DOSAGE REGIMEN OF AN S1P RECEPTOR AGONIST - S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial 3 to 6 days of treatment the daily dosage is raised so that in total the R-fold (R being the accumulation factor) standard daily dosage is administered and thereafter continued at the standard daily dosage or at a daily dosage lower than the standard daily dosage. | 03-22-2012 |
| 20140038919 | HEPATITIS C INHIBITORS AND USES THEREOF - This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 02-06-2014 |
| 20190144476 | NOVEL PHOSPHINOLACTONE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | 05-16-2019 |
